Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652623 · ClinicalTrials.gov registry record · Phase 1
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
A Phase 1 study of HIV/AIDS and Behavior and Behavior Mechanisms, sponsored by Hektoen Institute for Medical Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT03652623 is a Phase 1 study of HIV/AIDS and Behavior and Behavior Mechanisms that has completed, run by Hektoen Institute for Medical Research. The registered enrollment target is 49 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03652623, a Phase 1 study of HIV/AIDS and Behavior and Behavior Mechanisms, has completed, sponsored by Hektoen Institute for Medical Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
To address the critical scientific gaps in PrEP safety for transgender youth and to plan for appropriate implementation of PrEP in transgender youth communities, the study will be conducted in 3 integrated phases. In Phase 1, a pharmacokinetic (PK) study exploring the interactions of cs-HT for both TW and TM youth on TDF/FTC will be conducted. Simultaneously, in Phase 2, ethnographic data via focus groups (FGs) and in-depth interviews (IDIs) to inform the development of a tailored intervention to improve uptake and adherence to PrEP for transgender youth will be collected. In Phase 3, a small demonstration trial of PrEP use in transgender youth, utilizing the ethnographically developed intervention to improve uptake and adherence, while also monitoring renal and bone safety outcomes will be implemented. The project has the following important specific aims: Aim 1: To evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among 24 TW taking estradiol and 24 TM taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily adherence and maximize drug exposure. Aim 2: To develop a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth that is grounded in theory (Information-Motivation-Behavioral Skills Model of Behavior Change, Gender Affirmation, Empowerment Theory) and incorporates the PK data from Aim 1. The investigators will conduct FGs with young TW (N=20-30) and TM (N=20-30) and conduct IDIs with participants from the PK study (Total N=10-14). Investigators will solicit continuous input and feedback from TW and TM on the project's Youth Advisory Board. Aim 3: To conduct a small randomized controlled trial within a PrEP demonstration project comparing the newly developed intervention with standard of care (SOC) in TW (N=50) and TM (N=50) ages 15-24 years.
Conditions Studied
Interventions
- DRUG TDF/FTC
Study Locations (1)
Colorado
- University of Colorado, Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03652623
The ClinicalTrials.gov registry entry for NCT03652623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The listed sponsor is Hektoen Institute for Medical Research, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which TDF/FTC is the first listed.
NCT03652623 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03652623 about?
NCT03652623 is a clinical study titled "Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study". To address the critical scientific gaps in PrEP safety for transgender youth and to plan for appropriate implementation of PrEP in transgender youth communities, the study will be conducted in 3 integrated phases. In Phase 1, a pharmacokinetic (PK) study exploring the interactions of cs-HT for both ...
What is the current status of trial NCT03652623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-07-23. Estimated completion is 2023-11-30.
What conditions does trial NCT03652623 study?
This clinical trial studies the following conditions: HIV/AIDS, Behavior and Behavior Mechanisms, Gender.
What interventions are being tested in trial NCT03652623?
The interventions under investigation include: TDF/FTC (DRUG).
Who is sponsoring clinical trial NCT03652623?
This trial is sponsored by Hektoen Institute for Medical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03652623 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combinatorial Therapy to Induce an HIV Remission
ACTIVE NOT RECRUITING · Phase 1
-
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
COMPLETED · Phase 1
-
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens
COMPLETED · Phase 1
-
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
COMPLETED · Phase 1
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.